AZ and Novoheart collaborate on ‘heart in a jar’, to develop new HF drugsStem cell biotech Novoheart is to collaborate with AstraZeneca to develop a “heart in a jar” that will Share XAZ and Novoheart collaborate on ‘heart in a jar’, to develop new HF drugshttps://pharmaphorum.com/news/az-and-novoheart-collaborate-on-heart-in-a-jar-to-d/
Novartis eyes $5bn The Medicines Company acquisition – reportsNovartis is leading a group of companies that are considering buying US pharma The Medicines Company searching for Share XNovartis eyes $5bn The Medicines Company acquisition – reportshttps://pharmaphorum.com/news/novartis-eyes-5bn-the-medicines-company-acquisition-reports/
Amgen pulls higher-priced Repatha to try to lift salesMore than four years after Amgen’s cholesterol-lowering antibody Repatha was approved in the US, the company still can’t Share XAmgen pulls higher-priced Repatha to try to lift saleshttps://pharmaphorum.com/news/amgen-pulls-higher-priced-repatha-to-try-to-lift-sales/
FDA approves AZ’s Farxiga in new heart failure prevention useThe FDA has approved AstraZeneca’s diabetes drug Farxiga to reduce the chances of hospitalisations for heart failure in Share XFDA approves AZ’s Farxiga in new heart failure prevention usehttps://pharmaphorum.com/news/fda-approves-azs-farxiga-in-new-heart-failure-prevention-use/
AI-driven atrial fibrillation project begins after seed funding roundClinical development of an AI-driven system that identifies the sources or drivers of atrial fibrillation (AF), and could Share XAI-driven atrial fibrillation project begins after seed funding roundhttps://pharmaphorum.com/news/ai-driven-atrial-fibrillation-project-begins-after-seed-funding-round/
Heart failure results could unlock key market for Farxiga – AZAstraZeneca doesn’t quite know why its diabetes drug Farxiga is also working in patients with heart failure – Share XHeart failure results could unlock key market for Farxiga – AZhttps://pharmaphorum.com/news/heart-failure-results-could-unlock-key-market-for-farxiga-az/
FDA fast-tracks AZ’s Farxiga in potential new CKD indicationThe FDA has fast-tracked AstraZeneca’s Farxiga in a potential new use, to delay progression of renal failure and Share XFDA fast-tracks AZ’s Farxiga in potential new CKD indicationhttps://pharmaphorum.com/news/fda-fast-tracks-azs-farxiga-in-potential-new-ckd-indication/
AliveCor stops selling ECG wristband for Apple Watches – reportMobile ECG maker AliveCor has stopped sales of its FDA-approved ECG wristband for use with Apple Watches, according Share XAliveCor stops selling ECG wristband for Apple Watches – reporthttps://pharmaphorum.com/news/alivecor-stops-selling-ecg-wristband-for-apple-watches-report/
AZ’s Farxiga first in class to improve outcomes in heart failureAstraZeneca has scored a major trial victory after its Farxiga (dapagliflozin) became the first drug in its class Share XAZ’s Farxiga first in class to improve outcomes in heart failurehttps://pharmaphorum.com/news/azs-farxiga-first-in-class-to-improve-outcomes-in-heart-failure/
